-
11.发明公开
公开(公告)号：KR1020150008807A
公开(公告)日：2015-01-23
申请号：KR1020140077026
申请日：2014-06-24
Applicant: 전남대학교산학협력단
IPC: A61K36/605
CPC classification number: A61K36/605
Abstract: 본 발명은 시토크롬 P450 효소로 전환된 오디추출물을 포함하는 염증성장질환의 예방 또는 치료용 약학조성물에 관한 것으로, 상세하게는 시토크롬 P450 효소로 전환된 오디추출물로 염증성장질환을 완화시키고, 비정상적으로 과도화된 활성면역세포를 조절하는 약학조성물에 관한 것이다. 본 발명을 통해, P450 효소전환된 오디추출물이 대장 조직 내에 점막의 면역조절 활성을 유도함으로써, 염증성장질환의 개선, 예방 또는 치료에 유용하게 활용될 수 있을 것으로 기대된다.
Abstract translation: 本发明涉及用于预防或治疗炎性肠病的药物组合物，其包含细胞色素P450酶转化的桑叶提取物，更具体地，涉及通过使用细胞色素P450酶减轻炎症性肠病和控制异常超活化的活化免疫细胞的药物组合物 转化桑树提取物。 通过本发明，P450酶转化的桑树提取物诱导大肠组织中粘膜的免疫控制活性，从而用于缓解，预防或治疗炎症性肠病。
-
公开(公告)号：KR101402921B1
公开(公告)日：2014-06-02
申请号：KR1020130102400
申请日：2013-08-28
Applicant: 전남대학교산학협력단
Abstract: 본 발명은 비만 또는 제 2형 당뇨 치료를 위해 레스베라톨 유도체의 이용에 관한 것으로, 보다 상세하게는 피세아타놀(piceatannol), 피세이드(piceid) 또는 프테로스틸벤(pterostilbene)은 TREM-2 억제제로 작용할 수 있으며, 이에 의해 비만 또는 제 2형 당뇨의 예방 또는 치료에 이용할 수 있다. 또한 TREM-2(Triggering Receptor Expressed on Myeloid cells-2)를 억제함으로써 인슐린 대사와 관련된 유전자 및 지방세포 분화와 관련된 유전자의 발현조절을 제어할 수 있어 효과적으로 비만 또는 제 2형 당뇨를 치료하는데 유용하게 사용될 수 있는 장점이 있다.
-
公开(公告)号：KR101348984B1
公开(公告)日：2014-01-10
申请号：KR1020120009300
申请日：2012-01-31
Applicant: 전남대학교산학협력단
CPC classification number: C12P17/165 , C12N9/0042 , C12N9/0071 , C12Y114/14001
Abstract: 본 발명은 박테리아 시토크롬 P450을 이용한 오메프라졸로부터 대사산물의 신규한 생산방법 및 이를 위한 조성물에 관한 것으로, 보다 상세하게는 박테리아 시토크롬 P450 BM3(CYP102A1) 또는 그의 돌연변이체(mutant)를 포함하는 오메프라졸로부터 5'-히드록실산물 제조용 조성물, 키트 및 이의 생산방법으로, 상기의 조성물, 키트 및 제조방법은 경제적이면서 고효율로 오메프라졸로부터 5'-히드록실산물을 대량생산할 수 있기 때문에 오메프라졸(omeprazole)의 대사체를 이용한 신약개발에 크게 기여할 것이다.
-
14.发明公开
公开(公告)号：KR1020130088209A
公开(公告)日：2013-08-08
申请号：KR1020120009300
申请日：2012-01-31
Applicant: 전남대학교산학협력단
CPC classification number: C12P17/165 , C12N9/0042 , C12N9/0071 , C12Y114/14001
Abstract: PURPOSE: A composition and a method for preparing a 5-hydroxyl product are provided to cheaply and effectively produce a large amount of 5-hydroxyl products using wild type bacteria (CYP102A) and a mutant thereof and to develop a novel drug using the metabolite of omeprazole. CONSTITUTION: A composition for producing a 5'-hydroxyl product from omeprazole contains one or more enzymes selected among wild type CYP102A1 and a mutant thereof. The mutant has a changed sequence through one or more substitutions. A method for producing 5'-hydroxyl products from omeprazole comprises the step of reacting selected one or more enzymes with omeprazole. The mutant of CYP102A1 has changed sequences through one or more substitutions.
Abstract translation: 目的：提供一种制备5-羟基产物的组合物和方法，以便使用野生型细菌（CYP102A）及其突变体廉价有效地产生大量的5-羟基产物，并使用 奥美拉唑。 构成：用于从奥美拉唑生产5'-羟基产物的组合物含有选自野生型CYP102A1及其突变体中的一种或多种酶。 突变体通过一个或多个取代具有改变的序列。 从奥美拉唑制备5'-羟基产物的方法包括使所选择的一种或多种酶与奥美拉唑反应的步骤。 CYP102A1的突变体通过一个或多个取代改变序列。
-
公开(公告)号：KR1020170030902A
公开(公告)日：2017-03-20
申请号：KR1020150128399
申请日：2015-09-10
Applicant: 전남대학교산학협력단
CPC classification number: C12P19/46 , C12N9/0071 , C12Y114/14001
Abstract: 본발명은폴리데이틴의대사사산물중 아스트린진제조를위한조성물로서, 박테리아시토크롬 P450 효소인야생형 CYP102A1의환원효소영역과 CYP102A1 돌연변이체의헴영역을융합한 CYP102A1 키메라및 이의돌연변이체를촉매로이용하여폴레데이틴을산화시켜아스트린진을대량생산할수 있다.
Abstract translation: 使用聚天锡医疗纱纱产物作为用于制造石棉的组合物本发明修剪细菌细胞色素P450还原酶结构域和CYP102A1嵌合体，并且结合了酶的CYP102A1突变体的血红素域反突变体催化剂，野生型CYP102A1的让 氧化poreadeatin大规模生产收敛。
-
Patent Agency Ranking16.发明公开
公开(公告)号：KR1020160111609A
公开(公告)日：2016-09-27
申请号：KR1020150036428
申请日：2015-03-17
Applicant: 전남대학교산학협력단
IPC: A61K31/4184 , A61K31/44 , A23L1/30
CPC classification number: A61K31/4184 , A23L33/10 , A61K31/44
Abstract: 본발명의목적은기존의오메프라졸대비효소전환방법으로제조된오메프라졸대사체의우수한염증완화효과를가지는위궤양예방또는치료용조성물을제공하고자한다. 본발명은또 다른목적으로는기존오메프라졸대비우수한염증완화또는치료효과를가지는오메프라졸대사체를포함하는위궤양예방또는개선용건강식품을제공하고자한다.
Abstract translation: 本发明的目的是提供一种用于预防或治疗胃溃疡的组合物，与现有的奥美拉唑相比，通过酶转化方法制备的奥美拉唑的炎症减轻具有优异的效果。 本发明的另一个目的是提供一种用于预防或减轻胃溃疡的保健食品，其包含与现有的奥美拉唑相比具有优于减轻或治疗炎症的效果的奥美拉唑代谢物。
-
公开(公告)号：KR1020100096489A
公开(公告)日：2010-09-02
申请号：KR1020090015390
申请日：2009-02-24
Applicant: 전남대학교산학협력단
CPC classification number: A61K38/20 , C07K14/54 , C12N15/63 , Y10S514/824
Abstract: PURPOSE: A pharmaceutical composition containing interleukin, interleukin-24 agonist or gene encoding interleukin-24 is provided to treat or prevent hypertension or hypertension complication by suppressing expression of hypertension-associated gene. CONSTITUTION: A composition for preventing or treating hypertension contains interleukin-24, interleukin-24 agonist, gene encoding interleukin-24, mutant, or complement thereof. A gene encoding interleukin-24 is contained in viral or non-viral transporter. The composition additionally contains other material for treating hypertension.
Abstract translation: 目的：提供含有白介素，白细胞介素-24激动剂或编码白介素24的基因的药物组合物，通过抑制高血压相关基因的表达来治疗或预防高血压或高血压并发症。 构成：用于预防或治疗高血压的组合物含有白细胞介素-24，白细胞介素-24激动剂，编码白细胞介素-24，突变体或其补体的基因。 编码白细胞介素-24的基因包含在病毒或非病毒转运蛋白中。 该组合物另外含有用于治疗高血压的其它材料。
-
公开(公告)号：KR1020070078561A
公开(公告)日：2007-08-01
申请号：KR1020060008941
申请日：2006-01-27
Applicant: 주식회사 굿셀라이프 , 전남대학교산학협력단
IPC: C07K19/00 , C07K14/195 , C07K14/245
CPC classification number: C07K14/005 , A61K39/12 , A61K47/62 , C07K14/245 , C07K2319/00 , C12N15/70 , C12N2510/02 , C12N2710/20034
Abstract: A chimeric protein consisting of nontoxic CTB(cholera toxin B subunit) of Vibrio cholerae and HPV16 E7(human papilloma virus type 16 E7) protein and use thereof are provided to induce an antibody specific to HPV16 E7 and simultaneously induce mucosa immune response for promoting mucosa permeability of the antibody, so that the protein is useful as an effective ingredient of a vaccine for preventing and treating cervical cancer. The chimeric protein consisting of nontoxic CTB of Vibrio cholerae whose signal peptide region is deleted, and HPV16 E7 protein has the amino acid sequence of SEQ ID NO:6. A gene encoding the chimeric protein has the nucleotide sequence of SEQ ID NO:5. A method for producing the chimeric protein comprises the steps of: constructing a recombinant vector E7-CTB/pET29a containing the chimeric gene; transforming Escherichia coli with the vector to produce E. coli BL21(DE3):E7-CTB/pET29a(KCTC 10894BP); culturing the transformed E. coli; and separating the chimeric protein from the cultured E. coli, and purifying and removing endotoxin from the chimeric protein.
Abstract translation: 提供由霍乱弧菌无毒CTB（霍乱毒素B亚基）和HPV16 E7（人乳头瘤病毒16型E7）蛋白组成的嵌合蛋白及其用途，以诱导对HPV16 E7特异性的抗体，同时诱导促进粘膜的粘膜免疫应答 抗体的渗透性，使得该蛋白质可用作预防和治疗子宫颈癌的疫苗的有效成分。 由信号肽区域缺失的霍乱弧菌无毒CTB组成的嵌合蛋白质和HPV16E7蛋白质具有SEQ ID NO：6的氨基酸序列。 编码嵌合蛋白的基因具有SEQ ID NO：5的核苷酸序列。 制备嵌合蛋白的方法包括以下步骤：构建含嵌合基因的重组载体E7-CTB / pET29a; 用载体转化大肠杆菌以产生大肠杆菌BL21（DE3）：E7-CTB / pET29a（KCTC 10894BP）; 培养转化的大肠杆菌; 并从培养的大肠杆菌中分离嵌合蛋白质，并从嵌合蛋白质中纯化和去除内毒素。
-
公开(公告)号：KR1020070078560A
公开(公告)日：2007-08-01
申请号：KR1020060008940
申请日：2006-01-27
Applicant: 주식회사 굿셀라이프 , 전남대학교산학협력단
CPC classification number: C07K14/005 , A61K39/12 , A61K47/62 , C07K14/28 , C07K2319/00 , C12N15/63 , C12N2510/02 , C12N2710/20034
Abstract: A chimeric protein consisting of nontoxic CTB(cholera toxin B subunit) of Vibrio cholerae and HPV16 E6(human papilloma virus type 16 E6) protein and use thereof are provided to produce vaccine effectively absorbed to a mucosa for preventing and treating cervical cancer by using cervical cancer treating effects of HPV16 E6 protein and mucosa-penetrating ability of CTB. The chimeric protein consists of nontoxic CTB(cholera toxin B subunit) of Vibrio cholerae wherein the signal peptide region is deleted to remove toxicity, and HPV16 E6 protein, has the amino acid sequence of SEQ ID NO:6, is encoded by a gene having the nucleotide sequence of SEQ ID NO:5, and is produced by preparing a vector E6-CTB/pET29a containing the chimeric protein gene, transforming Escherichia coli with the vector to produce Escherichia coli BL21:E6-CTB/pET29a(KCTC 10892BP), culturing Escherichia coli BL21:E6-CTB/pET29a(KCTC 10892BP), separating the chimeric protein from the cultured transformed microorganism and removing endotoxin from the separated chimeric protein.
Abstract translation: 提供由霍乱弧菌无毒CTB（霍乱毒素B亚单位）和HPV16 E6（人乳头瘤病毒16型E6）蛋白组成的嵌合蛋白及其用途，以产生有效吸收到粘膜以预防和治疗宫颈癌的疫苗，方法是使用子宫颈 HPV16 E6蛋白的癌症治疗效果和CTB的粘膜穿透能力。 嵌合蛋白由霍乱弧菌的无毒CTB（霍乱毒素B亚基）组成，其中信号肽区缺失以消除毒性，HPV16E6蛋白具有SEQ ID NO：6的氨基酸序列，由具有SEQ ID NO：6的基因编码， SEQ ID NO：5的核苷酸序列，通过制备含有嵌合蛋白质基因的载体E6-CTB / pET29a，用载体转化大肠杆菌来产生大肠杆菌BL21：E6-CTB / pET29a（KCTC 10892BP）， 培养大肠杆菌BL21：E6-CTB / pET29a（KCTC 10892BP），从培养的转化微生物中分离嵌合蛋白质，并从分离的嵌合蛋白中除去内毒素。
-
20.发明公开
公开(公告)号：KR1020070078559A
公开(公告)日：2007-08-01
申请号：KR1020060008939
申请日：2006-01-27
Applicant: 주식회사 굿셀라이프 , 전남대학교산학협력단
IPC: C07K19/00 , C07K14/025 , C07K14/245
CPC classification number: C07K14/005 , A61K39/12 , C07K14/245 , C07K2319/00 , C12N15/70 , C12N2510/02
Abstract: A chimeric protein consisting of LTB(Escherichia coli heat-labile enterotoxin B subunit) and HPV16 E6(human papilloma virus type 16 E6) protein and use thereof are provided to induce an antibody specific to HPV16 E6 protein and mucosal immune response simultaneously, so that the chimeric protein is useful for production of a vaccine for preventing and treating cervical cancer. The chimeric protein consisting of LTB wherein the signal peptide region is deleted and HPV16 E6 protein has the amino acid sequence of SEQ ID NO:6 and is encoded by a gene having the nucleotide sequence of SEQ ID NO:5. A vector E6-LTB/pET29a contains the chimeric protein gene and is used for production of a transformed Escherichia coli BL21:E6-LTB/pET29a(KCTC 10893BP). The chimeric protein consisting of LTB and HPV16 E6 protein is produced by culturing the transformed Escherichia coli BL21:E6-LTB/pET29a(KCTC 10893BP), separating the chimeric protein from the cultured transformed microorganism and removing endotoxin from the separated chimeric protein.
Abstract translation: 提供由LTB（大肠杆菌热不稳定肠毒素B亚基）和HPV16 E6（人乳头瘤病毒16型E6）蛋白组成的嵌合蛋白及其用途，以同时诱导HPV16E6蛋白特异性抗体和粘膜免疫应答，从而 该嵌合蛋白质可用于生产用于预防和治疗子宫颈癌的疫苗。 由LTB组成的嵌合蛋白，其中信号肽区被缺失，HPV16E6蛋白具有SEQ ID NO：6的氨基酸序列，并由具有SEQ ID NO：5的核苷酸序列的基因编码。 载体E6-LTB / pET29a含有嵌合蛋白基因，用于生产转化大肠杆菌BL21：E6-LTB / pET29a（KCTC 10893BP）。 通过培养转化的大肠杆菌BL21：E6-LTB / pET29a（KCTC 10893BP），从培养的转化微生物中分离嵌合蛋白质并从分离的嵌合蛋白质中除去内毒素，产生由LTB和HPV16 E6蛋白组成的嵌合蛋白质。
-
-
-
-
-
-
-
-
-
Search Results
47
records
(took 0.026 seconds)
